Law360, New York (December 18, 2006, 12:00 AM ET) -- Eli Lilly & Co. downplayed the risks of its schizophrenia and bipolar disorder drug Zyprexa while also encouraging doctors to prescribe the drug for patients that had neither condition, according to company marketing documents.
A lawyer for patients gave the documents to the New York Times. The newspaper said that Lilly executives kept important information from doctors about Zyprexa’s ties to obesity and its tendency to raise blood sugar, both of which cause diabetes.
The Times said that Lilly’s published data has shown that 30% of...
Eli Lilly Disputes New York Times Report
To view the full article, take a free trial now.
